Novo Nordisk A/S - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US6701002056
36,72 € ↓ −1,56 (−4,08%)
2026-06-02
DELAT PRIS
SecurityDE:NOVA / Novo Nordisk A/S - Depositary Receipt (Common Stock)
InstitutionArlington Partners LLC
Latest Disclosed Ownership6,494 shares
Latest Disclosed Value $ 238,655
Arlington Partners LLC ownership in NOVA / Novo Nordisk A/S - Depositary Receipt (Common Stock)

On April 9, 2026 - Arlington Partners LLC filed a 13F-HR form disclosing ownership of 6,494 shares of Novo Nordisk A/S - Depositary Receipt (Common Stock) (DE:NOVA) valued at $204,886 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 0 shares of Novo Nordisk A/S - Depositary Receipt (Common Stock). The current value of the position is $238,460 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-09 2026-03-31 13F Novo Nordisk A COM 670100205 6,494 6,494 239 0.4763
2026-01-29 2025-12-31 13F Novo Nordisk A COM 670100205 0 -93,006 -100.00 0 -100.00
2025-10-28 2025-09-30 13F Novo Nordisk A COM 670100205 93,006 26,928 40.75 5,161 13.16 1.7833
2025-07-14 2025-06-30 13F Novo Nordisk A COM 670100205 66,078 16,733 33.91 4,561 33.10 1.6825
2025-04-23 2025-03-31 13F Novo Nordisk A COM 670100205 49,345 19,933 67.77 3,427 35.42 1.3446
2025-01-29 2024-12-31 13F Novo Nordisk A COM 670100205 29,412 0 0.00 2,530 -27.76 0.9822
2024-10-21 2024-09-30 13F Novo Nordisk A COM 670100205 29,412 5,935 25.28 3,502 4.51 1.3699
2024-08-06 2024-06-30 13F/A-1 Novo Nordisk A COM 670100205 23,477 -3,680 -13.55 3,351 -3.87 1.6639
2024-08-01 2024-06-30 13F Novo Nordisk A COM 670100205 23,477 -3,680 3,351 1.6639
2024-04-16 2024-03-31 13F Novo Nordisk A COM 670100205 27,157 -3,018 -10.00 3,487 11.69 1.7756
2024-01-24 2023-12-31 13F Novo Nordisk A COM 670100205 30,175 -1,177 -3.75 3,122 9.47 0.8974
2023-10-24 2023-09-30 13F Novo Nordisk A COM 670100205 31,352 17,641 128.66 2,851 28.54 1.1706
2023-07-26 2023-06-30 13F Novo Nordisk A COM 670100205 13,711 0 0.00 2,219 1.70 0.3423
2023-04-26 2023-03-31 13F Novo Nordisk A COM 670100205 13,711 -6,275 -31.40 2,182 -19.34 0.3104
2023-01-24 2022-12-31 13F/A-1 Novo Nordisk A COM 670100205 19,986 0 0.00 2,705 35.81 0.4288
2023-01-19 2022-12-31 13F Novo Nordisk A COM 670100205 19,986 0 3 0.4288
2022-10-28 2022-09-30 13F Novo Nordisk A COM 670100205 19,986 323 1.64 1,991 -9.13 0.7983
2022-07-25 2022-06-30 13F Novo Nordisk A COM 670100205 19,663 -4,992 -20.25 2,191 -19.98 0.7271
2022-04-14 2022-03-31 13F Novo Nordisk A COM 670100205 24,655 -3,676 -12.98 2,738 -13.71 0.7746
2022-01-18 2021-12-31 13F Novo Nordisk A COM 670100205 28,331 -3,957 -12.26 3,173 2.35 0.8522
2021-10-15 2021-09-30 13F Novo Nordisk A COM 670100205 32,288 -10,644 -24.79 3,100 -13.79 0.8924
2021-07-07 2021-06-30 13F Novo Nordisk A COM 670100205 42,932 1,003 2.39 3,596 27.20 1.2486
2021-04-19 2021-03-31 13F Novo Nordisk A COM 670100205 41,929 6,485 18.30 2,827 14.18 1.0348
2021-01-13 2020-12-31 13F Novo Nordisk A COM 670100205 35,444 418 1.19 2,476 1.81 1.1404
2020-10-15 2020-09-30 13F Novo Nordisk A COM 670100205 35,026 0 0.00 2,432 6.02 1.3333
2020-07-13 2020-06-30 13F Novo Nordisk A COM 670100205 35,026 -3,525 -9.14 2,294 -1.16 1.2884
2020-04-13 2020-03-31 13F Novo Nordisk A COM 670100205 38,551 30,866 401.64 2,321 421.57 1.2078
2020-01-16 2019-12-31 13F Novo Nordisk A COM 670100205 7,685 1,720 28.83 445 44.48 0.2730
2019-10-18 2019-09-30 13F Novo Nordisk A COM 670100205 5,965 -42,185 -87.61 308 -87.47 0.1956
2019-07-10 2019-06-30 13F Novo Nordisk A COM 670100205 48,150 43,190 870.77 2,458 849.03 1.1004
2019-04-05 2019-03-31 13F Novo Nordisk A COM 670100205 4,960 -22,990 -82.25 259 -79.89 0.1852
2019-01-10 2018-12-31 13F Novo Nordisk A COM 670100205 27,950 690 2.53 1,288 0.23 0.8376
2018-10-23 2018-09-30 13F Novo Nordisk A COM 670100205 27,260 380 1.41 1,285 3.63 0.9048
2018-07-11 2018-06-30 13F Novo Nordisk A COM 670100205 26,880 0 0.00 1,240 -6.34 1.1720
2018-05-07 2018-03-31 13F Novo Nordisk A COM 670100205 26,880 1,925 7.71 1,324 -1.12 1.2474
2018-01-29 2017-12-31 13F Novo Nordisk A ADR 670100205 24,955 24,955 1,339 1.3793
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.